Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227287 · ClinicalTrials.gov registry record
ADH1 and ADH2 Disease Monitoring Study (DMS)
A clinical trial of Autosomal Dominant Hypocalcemia, sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company.
- Active
- Registry status
- 95
- Enrollment target
- 20
- Study locations
NCT05227287: Active study of Autosomal Dominant Hypocalcemia, sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company.
NCT05227287 is a study of Autosomal Dominant Hypocalcemia that is active but no longer recruiting, run by Calcilytix Therapeutics, Inc., a BridgeBio company. The registered enrollment target is 95 participants. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05227287, a study of Autosomal Dominant Hypocalcemia, is active but no longer recruiting, sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company.
- ACTIVE NOT RECRUITING
- Registry status
- 95 participants
- Enrollment target
- 20
- Study locations
Study Summary
A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospective (over time into the future) data collection.
Conditions Studied
Study Locations (20)
Other
- Aarhus University Hospital - Aarhus
- Helsinki University Hospital (HUS) - The New Children's Hospital - Helsinki
- CHU de Lille - Lille
- Endokrinologikum Gottingen - Göttingen
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Ohio State University Medical Center (OSUMC) - Columbus
Auvergne-Rhône-Alpes
- HCL Hopital Femme Mere Enfant - Bron
- HCL Hopital Edouard Herriot - Lyon
California
- University of California, San Francisco (UCSF) - Benioff Children's Hospital - Oakland - Oakland
Colorado
- Children's Hospital Colorado - Aurora
Florida
- Nemours Children's Clinic - Jacksonville
Indiana
- Indiana University (IU) School of Medicine - University Hospital - Indianapolis
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2022-01-20 |
| Est. Completion | 2028-12 |
What the registry record for NCT05227287 still lists
NCT05227287 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 95 participants, a relatively small participant target.
The record links to 1 condition, with Autosomal Dominant Hypocalcemia appearing as the primary indexed condition, and to 0 interventions.
NCT05227287 names 20 study sites across 15 states, led by Other, Ohio, Auvergne-Rhône-Alpes.
Frequently Asked Questions
What is clinical trial NCT05227287 about?
NCT05227287 is a clinical study titled "ADH1 and ADH2 Disease Monitoring Study (DMS)". A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospec...
What is the current status of trial NCT05227287?
This trial is currently active not recruiting. The enrollment target is 95 participants. The study started on 2022-01-20. Estimated completion is 2028-12.
What conditions does trial NCT05227287 study?
This clinical trial studies the following conditions: Autosomal Dominant Hypocalcemia.
Who is sponsoring clinical trial NCT05227287?
This trial is sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05227287 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI